Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Corticobasal syndrome (CBS) is a combination of extrapyramidal disorders (asymmetric parkinsonism, dystonia, myoclonia) and cortical disorders (apraxia, disorders of complex types of sensitivity, the alien limb phenomenon). Most often, CBS is associated with corticobasal degeneration (CBD) or Alzheimer’s disease (AD). In some cases, differential diagnosis between these diseases based only on clinical and neuroimaging data is challenging. Biological markers for AD may prove crucial in establishing an accurate diagnosis. Two cases of patients with CBS and Alzheimer-type memory disorders are presented. Asymmetric cortical atrophy was detected by brain MRI. In the presented cases, patients showed a significant decrease in the Aβ42 levels in the cerebrospinal fluid, which helped to establish the diagnosis of AD. The issues of differential diagnosis of BSC associated with CBS and AD are discussed. The use of biomarkers for atypical clinical manifestations of AD may help to make a diagnosis early. Accurate diagnosis of AD is necessary both for the timely administration of available symptomatic drugs and for determining the indications for pathogenetic anti-amyloid therapy.

What this study adds

Evidence grade: Low

Two cases are presented in which patients with corticobasal syndrome and Alzheimer-type memory problems had significantly decreased Aβ42 levels in cerebrospinal fluid, which helped establish a diagnosis of Alzheimer's disease. The authors note that biomarkers can help diagnose atypical presentations of Alzheimer's early, which matters both for timely symptomatic treatment and for determining eligibility for anti-amyloid therapy.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Гришина, Д. А., Grinyuk, V. V., Nodel, M. R., Tyurina, A. Y., Mkhitaryan, E. A., & Chervyakova, Y. I. (2025). Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome. S S Korsakov Journal of Neurology and Psychiatry. https://doi.org/10.17116/jnevro2025125081133

Vancouver

Гришина ДА, Grinyuk VV, Nodel MR, Tyurina AY, Mkhitaryan EA, Chervyakova YI. Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome. S S Korsakov Journal of Neurology and Psychiatry. 2025. doi:10.17116/jnevro2025125081133. PMID: 40879241.

BibTeX

@article{study2025-40879241,
  author  = {Гришина, Д. А. and Grinyuk, V. V. and Nodel, Marina Romanovna and Tyurina, A. Yu. and Mkhitaryan, Elen A. and Chervyakova, Ya. I.},
  title   = {{Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome}},
  journal = {S S Korsakov Journal of Neurology and Psychiatry},
  year    = {2025},
  doi     = {10.17116/jnevro2025125081133},
  pmid    = {40879241},
  url     = {https://doi.org/10.17116/jnevro2025125081133}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Two cases are presented in which patients with corticobasal syndrome and Alzheimer-type memory problems had significantly decreased Aβ42 levels in cerebrospinal fluid, which helped establish a diagnosis of Alzheimer's disease. The authors note that biomarkers can help diagnose atypical presentations of Alzheimer's early, which matters both for timely symptomatic treatment and for determining eligibility for anti-amyloid therapy.

Study details

How this study scored 28/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 27 of the 96 points it could be judged on, which is 28 of 100. Total 28 of 100.27 of the 96 points we could judge = 28 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 27 of the 96 points we could judge it on, which is 28 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (S S Korsakov Journal of Neurology and Psychiatry)
Journal's citation record 0 / 4 S S Korsakov Journal of Neurology and Psychiatry: journal h-index 29 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Ya. I. Chervyakova holds only 3 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Sechenov University: institution h-index 284 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40879241)
Free to read 0 / 2 Behind a paywall — scores zero
Points 27 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 27 of the 96 points we could judge it on is 28 out of 100.
Total 28 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Treatments from nearby years

Also in Treatments

201 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →